Heitor Flavio Ferrari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heitor Flavio Ferrari has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Isabeli Joaquim Contel
Department of Pathology, Botucatu Medical School (FMB), São Paulo State University (UNESP), Botucatu, Brazil
2 shared publications - José Cândido Caldeira Xavier-Júnior
Instituto de Patologia de Araçatuba, Araçatuba, SP, Brazil; Faculty of Medicine, Centro Universitário Católico Unisalesiano, Araçatuba, SP, Brazil; Postgraduate Program in Pathology, Faculty of Medicine, Universidade Estadual Paulista, Botucatu, SP, Brazil
2 shared publications - Renée Laufer-Amorim
Department of Veterinary Clinic, School of Veterinary Medicine and Animal Science, São Paulo State University (Unesp), Botucatu, São Paulo, Brazil
2 shared publications - Fwu Shing Teng
Veterinary Clinic Department, São Paulo State University (UNESP)-School of Veterinary Medicine and Animal Science, Botucatu, Brazil
1 shared publication - Rafael Torres-Neto
VETMOL Diagnost Patologia Mol Veterinaria Pesquis, Botucatu, SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 7 May 2026
- Published by Brazilian Journal of Veterinary Pathology in Brazilian Journal of Veterinary Pathology
- Vol. 19, e019018
PRAME immunoexpression in canine melanocytic tumors: a case series study
Diffuse immunoexpression of Preferentially Expressed Antigen in Melanoma (PRAME) is an ancillary diagnostic tool for distinguishing human melanoma from melanocytic nevi. Canine melanocytic neoplasms are common in veterinary diagnostic practice; however, no established immunohistochemical biomarkers of malignancy are currently available. This case series study aimed to investigate the immunoexpression of the anti-PRAME (EPR20330) antibody in canine melanocytic tumors. Two cutaneous melanocytomas and six melanomas from distinct anatomical sites (haired skin, oral cavity and feet) were submitted to immunohistochemistry protocol with anti-PRAME antibody (clone EPR20330, dilution 1:100, Abcam) overnight at 4°C. Nuclear immunolabeling was scored on a 5-point scale based on the percentage of positive tumor cells (0: none; 1: 1–25%; 2: 26–50%; 3: 51–75%; 4/diffuse: ≥76%). The two evaluated melanocytomas were PRAME-negative. All melanomas were PRAME-positive and diffuse nuclear immunolabeling was observed in 4/6 cases. To the best of our knowledge, this is the first study to demonstrate the immunohistochemical expression of the anti-PRAME antibody (clone EPR20330) in canine melanomas. Our preliminary findings, based on a limited sample size, suggest that PRAME may represent a promising ancillary diagnostic marker for these tumors, similar to its use in human samples. However, further studies with larger cohorts are needed to better characterize its labeling patterns in canine melanocytic neoplasms and to confirm its diagnostic value in veterinary pathology.
- 7 May 2026
- Published by Brazilian Journal of Veterinary Pathology in Brazilian Journal of Veterinary Pathology
- Vol. 19, e019018
Open AccessPRAME immunoexpression in canine melanocytic tumors: a case series study
Diffuse immunoexpression of Preferentially Expressed Antigen in Melanoma (PRAME) is an ancillary diagnostic tool for distinguishing human melanoma from melanocytic nevi. Canine melanocytic neoplasms are common in veterinary diagnostic practice; however, no established immunohistochemical biomarkers of malignancy are currently available. This case series study aimed to investigate the immunoexpression of the anti-PRAME (EPR20330) antibody in canine melanocytic tumors. Two cutaneous melanocytomas and six melanomas from distinct anatomical sites (haired skin, oral cavity and feet) were submitted to immunohistochemistry protocol with anti-PRAME antibody (clone EPR20330, dilution 1:100, Abcam) overnight at 4°C. Nuclear immunolabeling was scored on a 5-point scale based on the percentage of positive tumor cells (0: none; 1: 1–25%; 2: 26–50%; 3: 51–75%; 4/diffuse: ≥76%). The two evaluated melanocytomas were PRAME-negative. All melanomas were PRAME-positive and diffuse nuclear immunolabeling was observed in 4/6 cases. To the best of our knowledge, this is the first study to demonstrate the immunohistochemical expression of the anti-PRAME antibody (clone EPR20330) in canine melanomas. Our preliminary findings, based on a limited sample size, suggest that PRAME may represent a promising ancillary diagnostic marker for these tumors, similar to its use in human samples. However, further studies with larger cohorts are needed to better characterize its labeling patterns in canine melanocytic neoplasms and to confirm its diagnostic value in veterinary pathology.
- 20 October 2025
- Published by Springer Nature in Veterinary Research Communications
- Vol. 49 (6) , 1-7
Canine cutaneous melanocytic tumors: main histopathological parameters and the use of a magenta chromogen in immunohistochemical diagnosis
Histopathological analysis remains the gold standard for diagnosing canine melanocytic tumors, and immunohistochemistry as an auxiliary tool. Given the challenge for immunohistochemical interpretation posed by melanin, a common pigment in the cytoplasm of canine neoplastic melanocytes, particularly when using 3,3’-diaminobenzidine (DAB) chromogen, this study aimed to evaluate the applicability of a magenta-colored chromogen for revealing the immunoreactivity of the well-established antibody Melan-A in 40 canine pigmented cutaneous melanocytic tumors and to analyze the association between several histopathological parameters and the diagnosis. Among the samples, 23 were classified as melanocytomas and 17 as melanomas. Significant associations were found between histopathological diagnosis and parameters such as ulceration, nuclear atypia, pigmentation, modified Clark level, symmetry, tumor margins, predominant cellular morphology, intratumoral necrosis, and lymphoplasmacytic inflammatory infiltrate (p < 0.05). A significant difference in the mean mitotic count was also observed between melanomas and melanocytomas (p < 0.05). All samples were positive for Melan-A. Most melanocytic tumors were heavily pigmented, and from these tumors, the majority exhibited strong cytoplasmic Melan-A immunostaining. The magenta chromogen provided excellent contrast with melanin and was visible in tumors regardless of pigmentation level. The findings of this study underscore the importance of analyzing specific histopathological parameters, which might help to differentiate benign from malignant lesions. Also, our results indicate that the magenta chromogen is both applicable and effective in the analysis of pigmented canine cutaneous melanocytic tumors, mitigating the interference caused by melanin and serving as a viable alternative to DAB in conventional immunohistochemistry. Additionally, these findings open perspectives for future studies applying the magenta chromogen to other melanocytic lineage markers.
- 20 October 2025
- Published by Springer Nature in Veterinary Research Communications
- Vol. 49 (6) , 1-7
Canine cutaneous melanocytic tumors: main histopathological parameters and the use of a magenta chromogen in immunohistochemical diagnosis
Histopathological analysis remains the gold standard for diagnosing canine melanocytic tumors, and immunohistochemistry as an auxiliary tool. Given the challenge for immunohistochemical interpretation posed by melanin, a common pigment in the cytoplasm of canine neoplastic melanocytes, particularly when using 3,3’-diaminobenzidine (DAB) chromogen, this study aimed to evaluate the applicability of a magenta-colored chromogen for revealing the immunoreactivity of the well-established antibody Melan-A in 40 canine pigmented cutaneous melanocytic tumors and to analyze the association between several histopathological parameters and the diagnosis. Among the samples, 23 were classified as melanocytomas and 17 as melanomas. Significant associations were found between histopathological diagnosis and parameters such as ulceration, nuclear atypia, pigmentation, modified Clark level, symmetry, tumor margins, predominant cellular morphology, intratumoral necrosis, and lymphoplasmacytic inflammatory infiltrate (p < 0.05). A significant difference in the mean mitotic count was also observed between melanomas and melanocytomas (p < 0.05). All samples were positive for Melan-A. Most melanocytic tumors were heavily pigmented, and from these tumors, the majority exhibited strong cytoplasmic Melan-A immunostaining. The magenta chromogen provided excellent contrast with melanin and was visible in tumors regardless of pigmentation level. The findings of this study underscore the importance of analyzing specific histopathological parameters, which might help to differentiate benign from malignant lesions. Also, our results indicate that the magenta chromogen is both applicable and effective in the analysis of pigmented canine cutaneous melanocytic tumors, mitigating the interference caused by melanin and serving as a viable alternative to DAB in conventional immunohistochemistry. Additionally, these findings open perspectives for future studies applying the magenta chromogen to other melanocytic lineage markers.